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Abstract Small non-coding RNAs include siRNA,
miRNA, piRNA and snoRNA. The involvement of miRNAs
in the regulation of mammary gland tumorigenesis has been
widely studied while the role for other small non-coding
RNAs remains unclear. Here we summarize the involvement
of miRNA in breast cancer onset and progression through
regulating the cell cycle and cellular proliferation. The regulation of breast cancer stem cells and tumor regeneration
by miRNA is reviewed. In addition, the emerging evidence
demonstrating the involvement of piRNA and snoRNA in
breast cancer is briefly described.
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Introduction
Small non-coding RNAs are transcribed into mRNA but
remain untranslated in eukaryotic cells. They include siRNA
(small interfering RNA), miRNA (microRNA), piRNA
(piwi-interacting RNA) and snoRNA (small nucleolar
RNA). miRNAs are a class of multifunctional singledstranded small RNA which are ~20 nt in length and regulate
the stability or translational efficiency of targeted messenger
RNA depending on the base-pairing complementarity between the miRNA and its target mRNA [1, 2]. Although
over 1,000 miRNA sequences have been identified from the
tissues or cells of human origin and other species, as many
as 1,000 to 10,000 miRNAs per genome have been predicted [3, 4]. miRNAs regulate a broad range of biological
processes including timing of development, cell cycle progression, stem cell self-renewal, differentiation, cancer initiation, cancer cell proliferation, metastasis and apoptosis
[5–11].
Cancer is caused by multiple processes including uncontrolled cellular proliferation and inappropriate survival of
apoptotic cells [12]. Many regulatory factors switch on or
off genes that govern cell division and direct cellular proliferation. miRNAs regulate gene expression and play important roles in the onset and progression of tumorigenesis.
Breast cancer is the most common cancer among women.
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Emerging evidence demonstrates the involvement of
miRNA in mammary gland tumorigenesis, functioning either as tumor suppressors or oncogenes [9]. Although the
current treatment of radiation therapy, chemotherapy and
hormone therapy slow mammary gland tumor growth, prolong survival and improve the quality of patients’ life,
metastatic breast cancer still remains incurable due to our
limited understanding of the molecular mechanisms through
which tumorigenesis and metastasis occur. As small noncoding RNAs regulate gene expression and tumorigenesis,
they may represent a novel cancer therapy.

Aberrant Expression of miRNA in Breast Cancer
Unlike mRNA, miRNAs are transcribed but never translated. Some miRNAs are transcribed from non-coding regions
between genes, deriving from independent transcription
unit. Other miRNAs are transcribed together with coding
mRNAs from the coding region of the genome, deriving
from the introns of gene transcripts [13, 14]. miRNA gene
copy number gain/loss and miRNA gene mutation have
been observed in breast cancer resulting in the aberrant
expression of miRNA. The first study about the altered
expression of miRNAs in human breast cancer patients
and human breast cancer cell lines was reported in 2005
by Lorio et al., in which 29 miRNAs were identified with
aberrant expression based on microarray and northern blot
analysis of 76 breast tumor samples and 14 human breast
cell lines [15]. Zhang and colleagues analyzed 283 human
miRNA genes on 55 human breast primary tumors and 18
human breast cancer cell lines using array-based comparative genomic hybridization. The results demonstrated a high
frequency (~72.8%) of gene copy number abnormality in
miRNA-containing regions in human breast cancer [16].
Wang et al. collected 68 patients with newly diagnosed
breast cancer and examined the expression of selected miRNAs in tumor and adjacent non-tumor tissues. miR-21, miR106a and miR-155 were significantly over-expressed in the
tumor specimens compared with normal controls, whereas
miR-126, miR-199a and miR-335 were significantly decreased in expression in the tumor samples [17]. Our studies
of the miR-17-92 cluster demonstrated decreased expression
of miR-17/20 in human breast cancer specimens compared
with matching normal breast tissue from the same patient
[18]. Subsequent analysis identified reduced miR-17/20 expression in node-positive compared with node-negative
breast cancers and demonstrated that miR-17/20 inhibited
breast cancer cell migration and invasion via a heterotypic
signaling [19].
Although the tendency for a global decrease of miRNA
expression in human cancers originally suggested a general
tumor suppressor function of miRNAs [20], subsequent
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studies showing the aberrant expression of specific miRNAs
in breast cancer suggest miRNA-specific roles in breast
cancer onset and progression.

miRNA Regulation of Cell Cycle and Mammary Gland
Tumorigenesis
Many distinct miRNAs have been shown to regulate breast
cancer cell proliferation, apoptosis, cancer stem cell expansion, and tumorigenesis. miRNA may function as either tumor
suppressors or oncogenes depending on the cell type, culture
conditions, target genes and pathway. The involvement of
miRNA in mammary gland tumorigenesis has been reviewed
recently [21, 22]. Le et al. described the expression pattern
and regulatory network of key miRNAs in breast cancer,
including let-7, miR-34, miR-125, miR-200 family, miR205, miR-21, miR-10 and the miR-17-92 cluster [22]. Adams
et al. reviewed the miRNA regulation of estrogen signaling
pathway and ErbB2/HER signaling pathway in breast cancer
[21]. The understanding of how miRNAs are involved in
breast cancer through regulating the cell cycle remains rudimentary. Herein we summarize the recent literature and research progress on the mechanism by which miRNAs regulate
the breast cancer cell cycle and cellular proliferation (Fig. 1).
Cyclin D1 is either overexpressed or amplified in ~50%
of breast cancer. The abundance of cyclin D1 is rate-limiting
in breast cancer cellular proliferation and G1-S phase transition [23, 24]. In addition, cyclin D1 is a critical downstream target of ErbB2-, Ras- and β-catenin- induced breast
cancers, and is sufficient for the induction of mammary
tumors when targeted to the mammary gland of mice. Antisense inhibition of cyclin D1 expression in vivo suppressed
the growth of NeuT-transformed mammary adenocarcinoma
cells in nude mice [25]. Conserved sequences of the cyclin
D1 3′UTR contain potential binding sites for multiple miRNAs including miR-17/20/106, miR-15/16, miR-23 and let7. miR-17/20 binds the cyclin D1 3′UTR, inhibiting the
expression of cyclin D1, resulting in cell cycle arrest at the
G1 phase and suppression of MCF-7 cell proliferation [18,
26]. The regulation of cyclin D1 expression by miR-17-92,
as well as miR-15/16, was confirmed by Deshpande et al.
[26]. The let-7 family functions as a tumor suppressor in a
variety of cancers including lung [27], colon [28], ovarian
[29] and breast cancer [30]. Schultz et al. demonstrated the
downregulation of cyclin D1 by miRNA let-7 in control of
cancer cell growth [31].
The regulation of cyclin D1 by miRNA is likely of broad
importance as cyclin D1 encodes the regulatory subunit of a
kinase that phosphorylates and inactivates the pRb family
proteins to inhibit DNA synthesis, and phosphorylates nuclear respiratory factor 1 (NRF-1) to inhibit mitochondria
biogenesis [32, 33]. Furthermore, cyclin D1 promotes breast
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Fig. 1 miRNA regulation of
mammary gland tumorigenesis
in control of the cell cycle.
Through targeting different
genes and different cyclin/CDK
complexes, miR-17/20 and let-7
regulate the G1-S transition;
miR-21 and miR-27a regulate
the G2-M checkpoint
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epithelial cell angiogenesis and migration [34], and promotes chromosomal instability which in turn contributes to
tumorigenesis [35].
The miR-221/222 cluster regulates the cell cycle, cell
growth and epithelial-to-mesenchymal transition (EMT) in
breast cancer. The expression of miR-221/222 is increased
in HER2/neu-positive primary human breast cancer [36].
The CDK inhibitors p27KIP1 and p57KIP2 are target genes
of miR-221/222. miR-221/222 inhibited p27 KIP1 and
p57KIP2 abundance, facilitating G1-S phase transition, thereby promoting cancer cell proliferation [36, 37]. Moreover,
miR-221/222 may contribute to the aggressive clinical behavior of basal-like breast cancers. The breast cancer basallike subtype-specific miRNAs, miR-221 and miR-222, promote EMT in breast cancer by targeting TRPS1 (trichorhinophalangeal syndrome type 1) which inhibits EMT by
repressing ZEB2 expression [38]. miR-221 and/or miR-222
expression in MCF-7 and T47D breast cancer cells decreased
ERα expression associated with tamoxifen resistance [39].
The onco-miRNA miR-21 is overexpressed in a wide
variety of cancers including breast cancer [40, 41]. miR-21
induced cellular proliferation, migration, invasion, EMT,
cancer stem cell characteristics and chemotherapy resistance
in human breast cancer [42, 43]. High miR-21 level is
associated with poor prognosis, advanced stage, positive
lymph node status and reduced survival time in breast
cancer. miR-21 promotes MCF-7 cellular proliferation in
part through inhibiting the expression of a tumor suppressor
gene programmed cell death 4 (PDCD4) [41]. In colon
cancer, miR-21 participates in a DNA damage-induced G2M checkpoint through suppressing the cell cycle regulator
Cdc25A [44]. A recent report demonstrated the miR-21
regulates the cell cycle through targeting Cdc25A in MCF7 breast cancer cells [45]. With a potential anti-cancer
chemical 3,3′-Diindolylmethane treatment, miR-21

expression increased, Cdc25A level decreased, and cellular
proliferation was inhibited [45].
miR-27a expression is upregulated in human breast cancer cell lines [46]. In MDA-MB-231 cells, miR-27a negatively regulated the zinc finger ZBTB10 gene and Myt-1,
thereby promoting breast cancer cell proliferation [47]. Myt-1
phosphorylates and inactivates cdc2/cyclin B, inhibiting the
mitotic initiation of cell cycle [48]. miR-27a suppressed
Myt-1, increased cdc2/cyclin B activity and promoted the
G2-M checkpoint in MDA-MB-231 cells. Thus, distinct
miRNAs affect key genetic targets that govern distinct
cell-cycle checkpoints including cyclins, CDKs, CDK
inhibitors and the G2-M regulation apparatus. In addition
to cell-cycle control, breast tumor onset and progression
and breast tumor stem cells are also regulated by distinct
miRNAs.

miRNA Regulation of Breast Cancer Stem Cells
Cancer stem cells (CSCs) are characterized by their selfrenewal capacity, an ability to differentiate into nontumorigenic cell progeny, and their ability to seed tumors
when transplanted into animal hosts [49]. Cell surface
markers such as CD44, CD24, CD133, epithelial-specific
antigen and aldehyde dehydrogenase-1 are frequently used
to isolate and enrich CSCs. CD44+CD24-/lowLineage- cells
were characterized as mammary gland tumorigenic CSCs
[50].
The involvement of miRNAs in regulating tumor formation by CSCs or tumor-initiating cells (T-IC) has been widely investigated. Let-7 expression is very low to undetectable
level in embryonic stem cells (ES cells) and increases with
differentiation. The same pattern of let-7 expression was
observed in breast cancer stem cells [30]. A comparison of
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miRNA expression between breast T-IC and non-T-IC demonstrated reduced let-7 expression in T-IC and increased
abundance with differentiation [30]. Transduction of breast
CSCs with let-7 reduced the proportion of undifferentiated
cells, inhibited cell proliferation, mammosphere formation,
and tumor formation in vivo [30].
Clarke and colleagues identified 37 miRNAs which were
differentially expressed between human breast CSCs
(CD44+CD24-/lowlineage-) and lineage- nontumorigenic breast
cancer cells [51]. miR-200 suppresses EMT in breast cancer
[52]. The miR-200 family members were downregulated in
human breast CSCs and normal mammary stem/progenitor
cells. Expression of miR-200 inhibited breast cancer stem cell
expansion in vitro, and suppressed the tumor formation ability
of human breast cancer stem cell in vivo [51].
Down-regulation of miR-34c was reported in human
breast T-IC [53]. Ectopic miR-34c expression reduced breast
T-ICs self-renewal, inhibited EMT and suppressed tumor
cell invasiveness via silencing Notch4 [53]. Zhu et al. found
the reduced miR-128 expression in human breast T-IC was
accompanied by Bmi-1 and ABCC5 overexpression, and
associated with chemotherapeutic resistance and poor survival [54]. Enforced miR-128 expression increased the sensitivity of breast cancer cells to doxorubicin-induced
apoptosis and DNA damage [54].
Emerging evidence has demonstrated the importance of
CSCs in cancer initiation, cancer metastasis and drug resistance. CSCs are believed to be one of the most promising
targets for cure of cancer. The discovery that non-coding RNAs
regulate CSCs widens our understanding of CSCs, and may
provide potential novel strategies for breast cancer therapy.

Other Non-coding Small RNAs in Breast Cancer
SnoRNAs primarily guide chemical modifications of other
RNAs. Deletion of chromosome 6q, including region 6q14q16, is frequently observed in breast cancer. The small noncoding snoRNA U50 is a candidate tumor suppressor gene
in the 6q14-16 region, playing a role in the development
and/or progression of breast cancer [55]. Genomic deletion
and transcriptional downregulation of snoRNA U50 was
detected in breast cancer cell lines. Re-expression of
snoRNA U50 inhibited colony formation of the human
breast cancer cells Hs578t and MDA-MB-231.
piRNAs are small non-coding RNA that form RNAprotein complexes through interactions with piwi proteins.
piRNA was initially discovered in germ line cells, and
considered as germ line-specific small RNAs [56]. Emerging evidence indicates that piRNA expression occurs in
somatic cells [57, 58] and piwil2 expression has been identified in human breast cancer cells [59]. High-throughput
deep sequencing identified a group of small RNAs matching
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piRNA sequences in human breast cancer tissues and breast
cancer cell lines [60].
The study of these non-coding small RNAs in human
cancer is just starting. The mechanisms regulating snoRNAs
and piRNAs in human breast cancer remain unknown. The
identification of the expression signature of these noncoding small RNAs in breast cancer subtypes, and an understanding of their functional significance to oncogene
expression, tumor initiation and tumor cell metastasis may
shed important new perspectives on the role of these noncoding small RNAs in breast cancer.

Therapeutic Application of miRNA
Small non-coding RNA-based diagnostic and therapeutic
applications for human cancer are expected in the near
future. Although tumor-targeted delivery and local administration are still major challenges to the practical application
of gene therapy for cancer, miRNA-based cancer therapeutic
approaches are being established and tested in animal models. Synthetic miRNA mimics or miRNA expression vectors
have been successfully applied to restore or overexpress
miRNA in vitro. Chemically modified LNA anti-sense
miRNA inhibitor and other approaches have been used to
block miRNA function in cells. Kim et al. recently reported
significant anti-tumor effect of virus-mediated delivery of
miR-145 combined with 5-FU to treat breast cancer [61].
Intranasal delivery of let-7 [62] and intravenous delivery of
miR-34a mimics [63] for non-small-cell lung cancer treatment and a virus-mediated delivery of miR-26a for liver
cancer treatment in mouse model [64] demonstrate the
promise of miRNA for treatment of cancer.

Concluding Remarks
Dysregulated expression of miRNAs has implicated components of the non-coding genome as either oncogenes or
tumor suppressors of breast cancer. Experimental evidence
has shown specific miRNAs regulating the initiation, progression, metastasis and drug resistance of breast cancer via
control of the cell cycle, altering cellular proliferation, altering cellular apoptosis and/or controlling the population of
tumor stem cells. Dysregulated miRNA expression has also
been observed in cancer associated fibroblasts (CAF) and in
the systemic circulation [65, 66]. The circulating miRNAs
have the potential to serve as novel diagnostic and prognostic biomarkers for breast cancer. A specific subset of dysregulated miRNAs in breast cancer cells may serve as targets
for gene therapy either alone or as an adjuvant treatment to
current clinical protocols for breast cancer patients.

J Mammary Gland Biol Neoplasia (2012) 17:59–64
Acknowledgement This work was supported in part by grants
81172515 from Natural Science Foundation of China and
2012CB966800 from National Basic Research Program of China (to
Yu , Z . ) ; R 0 1 C A 0 7 0 8 9 6 , R 0 1 C A 0 7 5 5 0 3 , R 0 1 C A 13 2 11 5 ,
R01CA107382, R01CA086072, P30CA56036 (R.G.P.); grants from
Pennsylvania Department of Health (R.G.P.), the Breast Cancer Research
Foundation, the Dr. Ralph and Marian C. Falk Medical Research Trust;
There are no conflicts of interest associated with this manuscript.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.

63

19.

20.

21.
22.
23.

References

24.

1. Ambros V. The functions of animal microRNAs. Nature. 2004;431
(7006):350–5.
2. Cullen BR. Transcription and processing of human microRNA
precursors. Mol Cell. 2004;16(6):861–5.
3. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et
al. Identification of hundreds of conserved and nonconserved
human microRNAs. Nat Genet. 2005;37(7):766–70.
4. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM,
et al. A pattern-based method for the identification of MicroRNA
binding sites and their corresponding heteroduplexes. Cell.
2006;126(6):1203–17.
5. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA
regulation of a human cellular signaling network. Mol Syst Biol.
2006;2:46.
6. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA.
miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007;3(5):521–37.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers.
Nature Reviews. 2006;6(11):857–66.
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri
S, et al. Human microRNA genes are frequently located at fragile
sites and genomic regions involved in cancers. Proc Natl Acad Sci U
S A. 2004;101(9):2999–3004.
9. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
10. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role
in cancer. Nature Reviews. 2006;6(4):259–69.
11. Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006;25(46):6220–7.
12. Hahn WC, Weinberg RA. Rules for making human tumor cells. N
Engl J Med. 2002;347(20):1593–603.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell. 2004;116(2):281–97.
14. Lin SL, Miller JD, Ying SY. Intronic microRNA (miRNA). J
Biomed Biotechnol. 2006;2006(4):26818.
15. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S,
et al. MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 2005;65(16):7065–70.
16. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis
A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006;103
(24):9136–41.
17. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of
microRNA aberrant expression in tissues and sera from patients
with breast tumor. Gynecol Oncol. 2010;119(3):586–93.
18. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, et al. A
cyclin D1/microRNA 17/20 regulatory feedback loop in

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

control of breast cancer cell proliferation. J Cell Biol.
2008;182(3):509–17.
Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al.
microRNA 17/20 inhibits cellular invasion and tumor metastasis in
breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A.
2010;107(18):8231–6.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et
al. MicroRNA expression profiles classify human cancers. Nature.
2005;435(7043):834–8.
Adams BD, Guttilla IK, White BA. Involvement of microRNAs in
breast cancer. Semin Reprod Med. 2008;26(6):522–36.
Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol
Oncol. 2010;4(3):230–41.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin
D1: normal and abnormal functions. Endocrinology. 2004;145
(12):5439–47.
Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB.
Amplification and expression of the human cyclin D gene in
esophageal cancer. Cancer Res. 1992;52(10):2980–3.
Lee RJ, Albanese C, Fu M, D’Amico M, Lin B, Watanabe G, et al.
Cyclin D1 is required for transformation by activated Neu and is
induced through an E2F-dependent signaling pathway. Mol Cell
Biol. 2000;20(2):672–83.
Deshpande A, Pastore A, Deshpande AJ, Zimmermann Y, Hutter G,
Weinkauf M, et al. 3′UTR mediated regulation of the cyclin D1
proto-oncogene. Cell Cycle. 2009;8(21):3584–92.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H,
Endoh H, et al. Reduced expression of the let-7 microRNAs in
human lung cancers in association with shortened postoperative
survival. Cancer Res. 2004;64(11):3753–6.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara
N, et al. MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299
(4):425–36.
Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et
al. MicroRNA microarray identifies Let-7i as a novel biomarker
and therapeutic target in human epithelial ovarian cancer. Cancer
Res. 2008;68(24):10307–14.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates
self renewal and tumorigenicity of breast cancer cells. Cell.
2007;131(6):1109–23.
Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let7b targets important cell cycle molecules in malignant melanoma
cells and interferes with anchorage-independent growth. Cell Res.
2008;18(5):549–57.
Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, et al. Cyclin D1
repression of nuclear respiratory factor 1 integrates nuclear DNA
synthesis and mitochondrial function. Proc Natl Acad Sci U S A.
2006;103(31):11567–72.
Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, et al.
Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol.
2006;26(14):5449–69.
Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, et al. Cyclin D1
induction of cellular migration requires p27(KIP1). Cancer Res.
2006;66(20):9986–94.
Casimiro M, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, et al.
ChIP-Sequencing of cyclin D1 in mouse reveals a transcriptional
role in chromosomal instability. J Clin Invest. 2012;Feb 6.
Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro
CL, et al. MicroRNA-221/222 confers tamoxifen resistance in
breast cancer by targeting p27Kip1. J Biol Chem. 2008;283
(44):29897–903.
Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, et al.
Functional links between clustered microRNAs: suppression of
cell-cycle inhibitors by microRNA clusters in gastric cancer.
Nucleic Acids Res. 2009;37(5):1672–81.

64
38. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O’Brien C, et al.
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci
Signal. 2011;4(186):pt5.
39. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem.
2008;283(45):31079–86.
40. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated
tumor growth. Oncogene. 2007;26(19):2799–803.
41. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A,
Lund AH. Programmed cell death 4 (PDCD4) is an important
functional target of the microRNA miR-21 in breast cancer cells.
J Biol Chem. 2008;283(2):1026–33.
42. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. HyaluronanCD44 interaction with protein kinase C(epsilon) promotes oncogenic
signaling by the stem cell marker Nanog and the Production of
microRNA-21, leading to down-regulation of the tumor suppressor
protein PDCD4, anti-apoptosis, and chemotherapy resistance in
breast tumor cells. J Biol Chem. 2009;284(39):26533–46.
43. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor
suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282
(19):14328–36.
44. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko Jr RJ, et al.
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69(20):8157–65.
45. Jin Y. 3,3′-Diindolylmethane inhibits breast cancer cell growth via
miR-21-mediated Cdc25A degradation. Mol Cell Biochem.
2011;358(1–2):345–54.
46. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid
alteration of microRNA levels by histone deacetylase inhibition.
Cancer Res. 2006;66(3):1277–81.
47. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein
transcription factors and the G2-M checkpoint in MDA-MB-231
breast cancer cells. Cancer Res. 2007;67(22):11001–11.
48. Booher RN, Holman PS, Fattaey A. Human Myt1 is a cell cycleregulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol
Chem. 1997;272(35):22300–6.
49. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or
reality? Nat Med. 2009;15(9):1010–2.
50. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke
MF. Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci U S A. 2003;100(7):3983–8.
51. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al.
Downregulation of miRNA-200c links breast cancer stem cells
with normal stem cells. Cell. 2009;138(3):592–603.
52. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid
G, et al. The miR-200 family and miR-205 regulate epithelial to

J Mammary Gland Biol Neoplasia (2012) 17:59–64

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell
Biol. 2008;10(5):593–601.
Yu F, Jiao Y, Zhu Y, Wang Y, Zhu J, Cui X, et al. MiR-34c downregulation via DNA methylation promotes self-renewal and
epithelial-mesenchymal transition in breast tumor-initiating cells.
J Biol Chem. 2012;287(1):465–73.
Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, et al. Reduced miR128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011;17
(22):7105–15.
Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W, et al. Implication
of snoRNA U50 in human breast cancer. J Genet Genomics.
2009;36(8):447–54.
Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A
germline-specific class of small RNAs binds mammalian Piwi
proteins. Nature. 2006;442(7099):199–202.
Lu Y, Li C, Zhang K, Sun H, Tao D, Liu Y, et al. Identification of
piRNAs in Hela cells by massive parallel sequencing. BMB Rep.
2010;43(9):635–41.
Lee EJ, Banerjee S, Zhou H, Jammalamadaka A, Arcila M, Manjunath
BS, et al. Identification of piRNAs in the central nervous system. RNA.
2011;17(6):1090–9.
Lee JH, Jung C, Javadian-Elyaderani P, Schweyer S, Schutte D,
Shoukier M, et al. Pathways of proliferation and antiapoptosis
driven in breast cancer stem cells by stem cell protein piwil2.
Cancer Res. 2010;70(11):4569–79.
Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H,
Morozov P, et al. MicroRNA sequence and expression analysis in
breast tumors by deep sequencing. Cancer Res. 2011;71(13):4443–53.
Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al.
Development of microRNA-145 for therapeutic application in
breast cancer. J Control Release. 2011;155(3):427–34.
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M,
et al. Regression of murine lung tumors by the let-7 microRNA.
Oncogene. 2010;29(11):1580–7.
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown
D, et al. Development of a lung cancer therapeutic based on the tumor
suppressor microRNA-34. Cancer Res. 2010;70(14):5923–30.
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery
CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses
tumorigenesis in a murine liver cancer model. Cell. 2009;137
(6):1005–17.
Rask L, Balslev E, Jorgensen S, Eriksen J, Flyger H, Moller S, et
al. High expression of miR-21 in tumor stroma correlates with
increased cancer cell proliferation in human breast cancer. APMIS.
2011;119(10):663–73.
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon
DS. Direct serum assay for microRNA-21 concentrations in early
and advanced breast cancer. Clin Chem. 2011;57(1):84–91.

